Ontology highlight
ABSTRACT:
SUBMITTER: Herring WJ
PROVIDER: S-EPMC4990943 | biostudies-literature | 2016 Sep
REPOSITORIES: biostudies-literature
Herring W Joseph WJ Connor Kathleen M KM Snyder Ellen E Snavely Duane B DB Zhang Ying Y Hutzelmann Jill J Matzura-Wolfe Deborah D Benca Ruth M RM Krystal Andrew D AD Walsh James K JK Lines Christopher C Roth Thomas T Michelson David D
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 20160915 9
<h4>Study objectives</h4>Suvorexant is an orexin receptor antagonist approved for treating insomnia at a maximum dose of 20 mg. Phase-3 trials evaluated two age-adjusted (non-elderly/elderly) dose-regimes of 40/30 mg and 20/15 mg with the primary focus on 40/30 mg. We report here results from pooled analyses of the 20/15 mg dose-regime, which was evaluated as a secondary objective in the trials.<h4>Methods</h4>Prespecified analysis of pooled data from two identical randomized, double-blind, plac ...[more]